Treatment with Mucuna pruriens Plus Solo Carbidopa Prescription in Patient Reluctant to Initiation of Traditional Levodopa/Carbidopa Medication
Objective: To see if treatment with Mucuna pruriens 2 capsules (15% levodopa) TID, plus solo carbidopa prescription 25mg TID in patient reluctant to traditional levodopa/carbidopa management could help…Medication therapy in Parkinson’s disease patients: a cross-sectional study at the University Medical Center at Ho Chi Minh City, Vietnam
Objective: To determine the rate of drugs prescribed to treat Parkinson's disease motor symptoms, the rate of the types of drug combinations, and the frequency…Phosphorylated High Mobility Group Box Protein 2 (HMGB2) as a Potential Biomarker for Parkinson’s Disease
Objective: We recently showed that HMGB2 is secreted during ferroptosis and as ferroptosis is involved in the etiology of PD, we have examined the possibility…The Moroccan LRRK2 Registry: Building Resources to Investigate the Penetrance and Phenotype of LRRK2 in North Africans
Objective: The Moroccan LRRK2 Registry aims to establish a comprehensive database integrating clinical data and biosamples to provide valuable insights into the penetrance, phenotype, and…Epigenome-wide and gene-targeted epigenetic profile of isolated REM Sleep Behaviour Disorder: a clinico-molecular study
Objective: Comprehensively characterize the epigenetic profile of isolated REM Sleep Behaviour Disorder (iRBD) using genome-wide and gene-targeted approaches, linking it to clinical measures and phenoconversion.…Facial Blendshape Index(FBI) for Quantification of Hypomimia on Parkinson´s Disease
Objective: To evaluate the validity of ExpressionTracker, an app generating personalized facial blendshapes, for objective quantification of hypomimia in patients with Parkinson’s disease (PD) [1].…Plasma P-tau217 detects Alzheimer’s co-pathology and predicts cognitive decline in Parkinson’s disease
Objective: The objectives of this study are to compare plasma phosphorylated tau-217 (P-tau217) levels in Parkinson’s disease (PD) with versus without Alzheimer’s disease (AD) copathology…Novel Usage of Alpha Synuclein as a Biomarker for Screening Parkinson’s disease at Komfo Anokye Teaching Hospital in Ghana
Objective: This study aimed to assess the use of alpha-synuclein as a biomarker for PD screening and investigate its correlation with disease severity. Background: The…Cognitive Improvement in Parkinson’s Disease Patients After Intravenous Mesenchymal Stem Cell Infusion: Results from a Phase 2 Randomized Trial
Objective: Assess the impact of treatment with intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cells (allo-hMSCs) on cognition in patients with mild-moderate Parkinson’s Disease (PD).…Modified Delphi consensus approach to develop recommendations for diagnosis, evaluation and management of cognitive disorders in Parkinson’s disease
Objective: We aimed to develop harmonised recommendations for the diagnosis, evaluation and management of cognitive disorders in PD using a modified Delphi process. Background: Differences…
- « Previous Page
- 1
- …
- 73
- 74
- 75
- 76
- 77
- …
- 181
- Next Page »